Frequently Asked Questions
The market is segmented based on , By Cancer Type (Lung Cancer, Breast Cancer, Colorectal Cancer, Leukaemia, Prostate Cancer, Cervical Cancer and Glioblastoma), Mechanism of Action Type (Tumour-associated Antigens (TAAs), Tumour-specific Antigens (TSAs), Somatic Mutations in Cancer Pharmacogenomics, Pharmacogenomics towards Genomic Polymorphism), Technology (Dendritic Cells (DC) Cancer Vaccines, Recombinant Cancer Vaccines, Antigen/Adjuvant Cancer Vaccines and Viral Vector and DNA Cancer Vaccines), Bio-maker Type (Pharmacogenomics, Prognostic and Predictive Biomarkers, Immune Checkpoint Biomarkers and Others), Treatment Type (Preventive Cancer Vaccines and Therapeutic Cancer Vaccines), Route of Administration (Injectable and Others), End-Users (Hospitals, Homecare, Specialty Clinics and Others) – Industry Trends and Forecast to 2030.
.
The Global Personalized Cancer Vaccines Market size was valued at USD 234790.00 USD Million in 2022.
The Global Personalized Cancer Vaccines Market is projected to grow at a CAGR of 5.9% during the forecast period of 2023 to 2030.
The market report covers data from the U.S., Canada, Mexico, Peru, Brazil, Argentina, Rest of South America, Germany, Italy, U.K., France, Spain, Netherlands, Belgium, Switzerland, Turkey, Russia, Hungary, Lithuania, Austria, Ireland, Norway, Poland, Rest of Europe, Japan, China, India, South Korea, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia Pacific, South Africa, Saudi Arabia, U.A.E., Kuwait, Israel, Egypt, Rest of Middle East and Africa.
